載入...
Neutropenia as a prognostic factor and safety of second-line therapy with S-1 for advanced or recurrent pancreatic cancer
The aim of this retrospective study was to investigate the safety of S-1 as second-line therapy and to evaluate the association between neutropenia occurring during first-line gemcitabine (GEM) therapy and survival for advanced or recurrent pancreatic cancer (APC). Between January, 2010 and December...
Na minha lista:
| 發表在: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
D.A. Spandidos
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4998036/ https://ncbi.nlm.nih.gov/pubmed/27588194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.940 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|